How to Get Evenity (Romosozumab) in District of Columbia

Who Qualifies for Evenity in DC

Evenity is FDA-approved for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies [1]. The FDA prescribing information carries a boxed warning about potential increased risk of myocardial infarction, stroke, and cardiovascular death, which means prescribers in DC must screen patients for cardiovascular history before writing a prescription.

In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months [2]. That reduction is what makes Evenity a preferred agent for patients who have already fractured or whose T-scores fall at or below -3.0 on dual-energy X-ray absorptiometry (DXA). DC-based clinicians typically reserve romosozumab for patients meeting the Endocrine Society's 2020 guideline criteria for "very high fracture risk," which includes a recent vertebral fracture within the past two years, a T-score at or below -3.0, or high FRAX probability [3].

Patients with a history of MI or stroke within the prior 12 months are excluded. So are patients with uncorrected hypocalcemia.

Prescriber Options: MD, NP, and PA Authority in DC

District of Columbia grants full practice authority to nurse practitioners. An NP in DC can independently evaluate, diagnose, and prescribe Evenity without physician supervision, per DC Code § 3-1206.04. Physician assistants may also prescribe under a collaborative agreement with a supervising physician.

The most common prescribers for romosozumab in DC are endocrinologists and rheumatologists, though primary care physicians comfortable with osteoporosis management can prescribe it. Finding a prescriber is simpler in DC than in rural states because of the concentration of academic medical centers. Georgetown, GW, and MedStar each have bone health clinics with experience managing romosozumab's prior authorization paperwork.

Any licensed DC prescriber with a valid DEA registration (romosozumab is not a controlled substance, but the DEA number is often required for specialty pharmacy processing) can initiate the prescription. The bottleneck is rarely the prescriber. It is the insurer.

Telehealth Access for Evenity in DC

DC permits telehealth prescribing of Evenity. A licensed provider can conduct a video consultation, review DXA scans and lab results uploaded to a patient portal, and transmit the prescription to a specialty pharmacy electronically.

Telehealth works well for the initial evaluation and follow-up visits, but the monthly injections themselves require either an in-office visit or home health nursing, since romosozumab is a subcutaneous injection that comes in prefilled syringes requiring proper technique. Some patients self-inject after training, though many DC-area practices prefer supervised administration for at least the first three doses.

DC's telehealth parity law (DC Code § 31-3861) requires private insurers to reimburse telehealth visits at the same rate as in-person visits, which removes a financial barrier for patients who prefer remote consultations [4]. Medicaid managed care plans in DC (operated through AmeriHealth Caritas and other MCOs) also cover telehealth-initiated prescriptions for specialty drugs, provided the drug itself meets prior authorization criteria.

One practical note: the prescriber must hold an active DC license. An out-of-state telehealth provider cannot prescribe Evenity to a DC resident unless that provider is also licensed in the District.

Labs Required Before Starting Evenity in DC

Before the first injection, DC prescribers order a standard pre-treatment workup. This is not optional. Insurers require documentation of these results for prior authorization.

Serum calcium must be within normal limits (8.5 to 10.5 mg/dL). Hypocalcemia is a contraindication. Patients with low calcium need repletion and retesting before initiation.

25-hydroxyvitamin D should be at or above 30 ng/mL. Deficiency is common in DC residents, particularly during winter months when UV exposure drops. Prescribers typically start high-dose vitamin D3 (50,000 IU weekly for 8 weeks) and recheck before beginning romosozumab.

DXA scan results are mandatory. Most insurers require a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip. Some plans require a T-score at or below -3.0 or documented fragility fracture.

Basic metabolic panel (BMP) screens for renal function. Severe renal impairment does not require dose adjustment per the FDA label, but clinicians monitor creatinine and eGFR given the patient population's age profile.

Cardiac risk assessment matters. The ARCH trial observed a numerically higher rate of serious cardiovascular events in the romosozumab group (2.5%) compared to alendronate (1.9%) [2]. DC prescribers should document cardiovascular risk assessment and confirm no MI or stroke in the prior 12 months.

Labs are typically drawn 2 to 4 weeks before the target start date to allow time for correction of any deficiencies and completion of prior authorization.

Prior Authorization in DC: Step-by-Step

Every commercial insurer and DC Medicaid requires prior authorization for Evenity. The drug's wholesale acquisition cost exceeds $1,800 per monthly dose, which places it in the specialty tier for virtually all formularies.

Step 1: Clinical documentation. The prescriber's office assembles the DXA scan report, lab results (calcium, vitamin D, BMP), cardiovascular screening documentation, and a letter of medical necessity. The letter must specify the patient's fracture history, prior osteoporosis treatments tried (most plans require failure of or intolerance to a bisphosphonate or denosumab), and the clinical rationale for romosozumab.

Step 2: Submission. The prior authorization request goes to the insurer's pharmacy benefit manager. In DC, CareFirst BlueCross BlueShield, Aetna, United, and Cigna each have their own PA forms. DC Medicaid processes PAs through its fee-for-service pharmacy program or through the assigned MCO.

Step 3: Review timeline. Federal and DC regulations require insurers to respond to standard PA requests within 72 hours for urgent requests and 14 calendar days for non-urgent requests. In practice, most specialty PAs for Evenity in DC receive a decision within 5 to 7 business days.

Step 4: Appeals. If denied, the prescriber can submit a peer-to-peer review. Denial rates for romosozumab are not trivial. A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that sclerostin inhibitor PAs had initial denial rates near 30% across commercial plans, though most were overturned on appeal when documentation was complete [5].

DC Medicaid covers Evenity for severe osteoporosis with PA. The Medicaid PA form requires ICD-10 codes (M80.x for age-related osteoporosis with pathological fracture or M81.0 for age-related osteoporosis without pathological fracture) and documentation of DXA T-score results.

Specialty Pharmacy and 503A Access in DC

Evenity is dispensed through specialty pharmacies, not retail pharmacies. The drug requires cold-chain storage (2°C to 8°C) and ships in insulated packaging with temperature monitors.

Major specialty pharmacies operating in DC include CVS Specialty, Optum Specialty, and Accredo. These pharmacies coordinate with the prescriber's office on PA status, ship directly to the patient's home or the administering clinic, and provide patient support services including copay assistance enrollment.

503A compounding pharmacies in DC are licensed and may dispense romosozumab under patient-specific prescriptions. A 503A pharmacy compounds or dispenses medications pursuant to a valid prescription for an individual patient, as governed by Section 503A of the Federal Food, Drug, and Cosmetic Act. For a branded biologic like Evenity, 503A pharmacies would dispense the commercial product rather than compound a biosimilar, since no FDA-approved biosimilar for romosozumab exists as of May 2026.

DC-licensed pharmacies can ship within the District. Patients living near the Maryland or Virginia borders should confirm their delivery address falls within DC jurisdiction if their prescription is filled at a DC-licensed pharmacy.

What to Expect During 12 Months of Treatment

Romosozumab is given as two subcutaneous injections (one in each prefilled syringe, 105 mg each, 210 mg total) once per month for exactly 12 doses [1]. There is no approved regimen longer than 12 months.

The injection sites rotate between the abdomen, thigh, and upper arm. Each injection takes about 30 seconds to deliver. Most DC practices schedule monthly 15-minute visits for administration, though some train patients on self-injection after the first two supervised doses.

Common side effects include injection site reactions (5.2% in clinical trials), arthralgia (12.4%), and headache (5.5%) [1]. The FRAME trial (N=7,180) reported that romosozumab increased lumbar spine bone mineral density by 13.3% at 12 months compared to 0% for placebo [6].

After the 12-month course, patients must transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to maintain bone density gains. Stopping without a follow-on therapy leads to rapid bone loss, similar to the rebound phenomenon seen with denosumab discontinuation. The Endocrine Society recommends planning the transition agent before the first romosozumab injection [3].

Follow-up DXA is typically performed at 12 months (just before or just after the final dose) to document treatment response. Repeat labs include serum calcium and 25-hydroxyvitamin D.

Cost and Financial Assistance in DC

The list price for Evenity is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course. Out-of-pocket costs depend entirely on insurance.

Amgen's Evenity copay card covers up to $10,000 per year in copay assistance for commercially insured patients, potentially reducing the monthly out-of-pocket cost to $0 to $5 per injection [7]. This card does not apply to patients on Medicare, Medicaid, or other government insurance.

For Medicare Part B patients (Evenity is covered under Part B as a physician-administered injectable), the 20% coinsurance after the deductible can reach $300 to $400 per month. Medigap plans or Medicare Supplement policies may cover this coinsurance.

DC Medicaid patients pay no cost-sharing for covered specialty drugs once PA is approved, per DC Medicaid's zero cost-sharing policy for most outpatient prescription drugs.

The Amgen Safety Net Foundation provides free Evenity to uninsured patients who meet income eligibility requirements (generally at or below 400% of the federal poverty level) [7].

Cardiovascular Safety Monitoring

The ARCH trial's cardiovascular signal requires ongoing vigilance. In ARCH, adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 12 months of romosozumab treatment [2]. The FDA's Drug Safety Communication advises prescribers to consider whether the benefits outweigh the risks for each individual patient.

DC prescribers should perform a baseline cardiovascular assessment including blood pressure measurement and review of cardiac history. Patients who develop symptoms of MI or stroke during treatment should discontinue romosozumab and receive immediate evaluation.

A 2021 meta-analysis in the Journal of Bone and Mineral Research (N=14,081 across four trials) found no statistically significant increase in MACE with romosozumab compared to placebo, though the point estimate favored caution in high-risk patients [8]. The signal was driven by the active-comparator ARCH trial rather than the placebo-controlled studies.

Transferring a Prescription to DC

Patients relocating to DC from another state can transfer an active romosozumab prescription. The process requires the new DC-licensed prescriber to verify the original prescription, confirm the patient's treatment month (e.g., dose 7 of 12), and resubmit prior authorization to the patient's insurer under the DC-based provider's NPI number.

If the patient switches insurers during the move, a new PA is required. Bringing copies of the original PA approval letter, DXA reports, and lab results speeds the process. Most specialty pharmacies can transfer patient records internally if the patient remains within the same pharmacy network (for example, CVS Specialty in Virginia to CVS Specialty servicing DC).

DC does not require a new DXA scan for transferred patients if the existing scan is less than 24 months old. A new cardiovascular screening visit with the DC prescriber is recommended but not legally mandated.